World Evidence-based Heathcare Day is held on 20 October each year. It is a global initiative that raises awareness of the need for better evidence to inform healthcare policy, practice and decision making in order to improve health outcomes globally. It provides an opportunity to participate in debate about global trends and challenges, but also to celebrate the impact of individuals and organisations worldwide, recognising the work of dedicated researchers, policymakers and health professionals in improving health outcomes.

Cochrane has partnered with JBI, Campbell Collaboration, the Institute for Evidence-Based Healthcare, the Centre for Evidence-based Health Care, the Institute for Development Studies and the Applied Health and Research Unit (AHRU) at the University of Oxford to launch the 2024 campaign for World Evidence-Based Healthcare (EBHC) Day, called ‘Health and Beyond: From Evidence to Action’.

By facilitating dialogue and knowledge-sharing across sectors, World EBHC Day 2024 serves as a global platform to share and access collective knowledge and wisdom for health and beyond, moving from evidence to action, while highlighting that intersectoral collaboration and innovation is pivotal to transformative change.

Cochrane’s Editor-in-Chief, Karla Soares-Wesier, spoke with the campaign partners at the Global Evidence Summit, where she said that:

“Cochrane has long led the way in evidence synthesis, but we recognize we can’t do it alone. Collaboration is essential, and working closely with our partners is key. There is a growing movement to create more opportunities for joint efforts in producing evidence that supports decision-making and ultimately saves lives. To achieve this, we need to be present at the table and ensure our partners—whether from high-income or low- and middle-income settings—are there with us.”

This was at part of the Connected Conversations series, which is a new initiative that aims to provide the global evidence community with a glimpse of people's professional and personal journeys using evidence-based approaches to take action for health and beyond. Cochrane received contributions from Dr Celeste Naude the Director Cochrane Nutrition, Dr Carlotte Kiekens the Co-Director Cochrane Rehabilitation, Dr Ali Akbar Haghdoost the Ex-Director Cochrane Iran, Dr Vignesh Kumar Chandiraseharan from Cochrane India, and Jack Nunn from the Cochrane Consumer Network.

Cochrane World EBHC Day events

Cochrane Croatia hosted a in-person symposium titled Modern Views on Mental Health: Incorporating Evidence-Based Medicine for Effective Health Care. Held at the Faculty of Medicine in Split, it included discussions on better evidence for mental health, supporting mental health in the community, and the use of chatbots in psychiatry, among a wide variety of other topics.

Cochrane Y3 mentees from the Cochrane US Network hosted a free webinar titled 'Beyond a Publication: How Evidence-Based Healthcare Changes Communities.'

Cochrane World EBHC Day blogs

• Including people with lived experience in evidence-informed approaches
• Global health requires embracing planetary health from an early age
• The importance of knowledge translation (and trust) in polycrisis times
• Maternal mortality in Ecuador: more than just a health care problem
• Intersectoral action: Including local economic considerations in health guidelines
• How Cochrane Germany is Advocating for Clinical Trial Transparency through Collaboration

Cochrane World EBHC Day vlogs

World Evidence-Based Healthcare Day 2024 is an opportunity to engage with a global community dedicated to advancing evidence-informed health policies and practices. We invite you to join the conversation, share your insights, and take action for health and beyond.

If you have Cochrane-related events to add to our listing above, please contact Mia Parkinson.

For more information about World EBHC Day 2024 and how you can participate, please contact Mariam Salman or visit the official campaign website: https://worldebhcday.org/

Title: Editorial Assistant 
Specifications: Full Time Permanent Contract
Salary: £26,000 per annum
Location: Flexible (remote)
Application Closing Date: 22 October 2024 (midnight GMT)

Cochrane has established a Central Editorial Service to support the efficient and timely publication of high-quality systematic reviews in the Cochrane Library. The reviews that are published through the Central Editorial Service address some of the research questions considered to be the most important to decision makers. 

The Editorial Assistant will perform editorial tasks to support the smooth running of the Editorial Service. Tasks will include, but are not limited to: performing checks on manuscripts on submission and before publication; supporting the peer-review process including inviting peer reviewers and tracking progress; assisting authors and peer reviewers to use Cochrane’s Editorial Management System; running editorial reports for the Editorial Service Executive Editor; arranging and preparing documents for editorial meetings; and supporting the Head of Editorial in projects aimed at improving or developing editorial systems and processes.

Cochrane is a global independent network of health practitioners, researchers, patient advocates and others, responding to the challenge of making the vast amounts of evidence generated through research useful for informing decisions about health. We do this by identifying, appraising and synthesizing individual research findings to produce the best available evidence on what can work, what might harm and where more research is needed.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 22 October 2024 (midnight GMT).
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Note that we will assess applications as they are received, and therefore may fill the post before the deadline.
• Read our Recruitment Privacy Statement

Cochrane’s systematic reviews are playing a key role in informing the World Health Organization’s (WHO) guidelines for managing preterm infants, including respiratory interventions. These reviews, led by Cochrane Sweden and Cochrane Neonatal, are providing the evidence that is directly shaping recommendations on treatments like caffeine therapy to support lung function in preterm babies. 

Preterm birth remains one of the leading causes of infant mortality worldwide. In response, the WHO regularly updates its guidelines to enhance care and improve outcomes for these vulnerable infants. By basing its recommendations on the latest and most reliable data from Cochrane reviews, the WHO ensures that its guidance remains both relevant and evidence based. 

“Our guideline development process is very rigorous and evidence-based,” says Marge Reinap Technical Officer, Evidence-based Policy at the WHO. “All our questions and recommendations rely on evidence synthesis. Without evidence synthesis, the guideline development panel cannot issue a recommendation. The evidence synthesis developed by Cochrane is instrumental and serves as the pillar point of WHO’s normative guidance, facilitating discussions and forming recommendations.”  

The collaboration began when the WHO commissioned Cochrane Sweden and Cochrane Neonatal to conduct systematic reviews on interventions for preterm infants. These reviews, led by Matteo Bruschettini, Director of Cochrane Sweden, explored the evidence around caffeine to improve health outcomes for preterm infants. Studies have shown that caffeine therapy improves lung function and reduces both mortality and long-term disabilities in preterm infants. 

The impact of these Cochrane reviews on WHO guidelines was immediate. The evidence gathered was directly incorporated into the WHO’s updated recommendations on the care of preterm infants, giving healthcare providers around the world clear, evidence-based guidance to improve the survival and health outcomes of these infants. 

Beyond influencing global policy, Cochrane Sweden is now working on adapting the WHO guidelines for the Swedish healthcare system. This framework, known as ‘GRADE ADOLOPMENT’, involves modifying guidelines made by others to fit specific national contexts. GRADE refers to the ‘Grading of Recommendations, Assessment, Development and Evaluation’ approach, while ‘ADOLOPMENT’ means adopting, adapting, and/or developing new recommendations. 

“Combining the strengths of the Cochrane network, evidence and methodologies with the GRADE ADOLOPMENT framework is very helpful for making recommendations applicable to the Swedish setting,” says Matteo Bruschettini. “It’s an efficient way to make tailored recommendations based on solid foundations, without duplicating efforts.” 

Cochrane Sweden, in collaboration with the WHO and members from the GRADE Working Group are working towards that the adapted guideline are tailored to the Swedish needs and healthcare environment while maintaining the same high standard of evidence-based recommendations. 

While WHO’s guidelines provide a comprehensive framework, countries often need to adjust them to align with their healthcare systems. In Sweden, Cochrane’s work focuses on ensuring that the guidelines not only address local concerns but also meet the practical needs of healthcare providers. This demonstrates how robust global evidence can be translated into actionable, country-specific recommendations. 

“We’re in the process of making guidelines made by others more used in the Swedish setting,” says Martin Ringsten, Project Coordinator at Cochrane Sweden. “It would save a lot of time and resources to use the evidence included in guidelines made by others. Guideline developers can then adopt or adapt recommendations and add contextual evidence where it’s needed.”  

Cochrane Sweden’s involvement in the development and adaptation of these guidelines and included systematic reviews highlights how systematic reviews inform clinical guidelines and public health policy. This collaboration ensures that healthcare recommendations are based on the best available evidence and contextualized to the applicable settings, thereby enhancing the quality and relevance of healthcare practices at both global and national levels. 

The process of using and contextualizing guidelines for specific settings illustrates how Cochrane reviews integrated into these guidelines can directly impact healthcare practice and policy, both globally and nationally. 

The World Health Organization (WHO) has recently launched new guidance on best practices for clinical trials. The document aims to reinforce global standards in the organization, design, conduct, analysis and reporting of clinical trials. It responds to calls in World Health Assembly resolution 75.8, which emphasized the urgent need to enhance both global and national clinical trial ecosystems to generate high-quality evidence on health interventions. 

Cochrane’s Editor in Chief, Dr Karla Soares-Weiser, contributed to the technical advisory group established to support the resolution and this guidance. 

The WHO guidance offers practical recommendations to assist national health authorities, regulatory authorities, funders and others in facilitating effective clinical trials and research. Key recommendations centre on improving trial design to ensure the relevance of research; an emphasis on scientific and ethical standards; strengthening of capacity and support for sustainable research infrastructure; enhancing clinical trial transparency; and reforms to enable underrepresented groups to participate in clinical trials. 

Eva Madrid, the Lead of Cochrane’s new Iberoamérica Evidence Synthesis Unit, spoke on the panel of the launch event for the new guidance. She highlighted the need for greater engagement between those conducting clinical trials and the evidence synthesis community. Eva stated: 

“Disregarding existing evidence leads to redundant findings and fails to prioritize the gaps that we need to fill, missing the opportunity to resolve clinical uncertainties with clinical trials." 

In his opening  statement, Dr Jeremy Farrar, WHO Chief Scientist, said: “Clinical trials are the bedrock of clinical and public health policymaking and evidence informed policymaking” and urged that they should not only be set up in times of crisis and are used for “answering critically important and clinical and public health questions all of the time.” 

If you would like to find out more about Cochrane’s work on clinical trials, please get in touch with the Advocacy and Partnerships Team: msalman@cochrane.org

Cochrane is excited to announce The People’s Review, a project designed to empower individuals worldwide to take part in a systematic review. The People’s Review invites the public to learn about systematic reviews by directly participating in the process. The People's Review is brought to you by Evidence Synthesis Ireland and Cochrane Ireland.

The People’s Review will be hosted on the Cochrane Crowd platform, which already supports various citizen science tasks related to systematic reviews. It will help guide participants through eight interactive stages— from choosing the review question to sharing the final results.

What Makes The People’s Review Special?

In an age of overwhelming information and online health advice, it’s crucial to have tools that allow individuals to navigate complex medical data. Systematic reviews offer a structured and reliable way to assess healthcare treatments. By involving the public in conducting one, The People’s Review seeks to demystify the process and equip participants with essential critical thinking skills for health decision-making.

 Éle Quinn, is a PhD student at University of Galway and is working alongside Evidence Synthesis Ireland and Cochrane Ireland on this project. Éle is the lead behind The People’s Review and shares her enthusiasm for the project and its potential impact:

"The People’s Review opens up the world of systematic reviews to the public, giving people the opportunity to directly participate in and learn about evidence-based healthcare. We believe that everyone has the right to be involved in research, and this project brings that vision to life!"

The Cochrane Crowd platform hosts tasks that help identify and describe health research for systematic reviews. Many within the Crowd community have fed back that the experience helps build skills around understanding health evidence. Each task is always supported by brief (and fun!) interactive training, and any contribution is welcome. Anna Noel-Storr, Cochrane Crowd Lead adds:

"We’re thrilled to be part of this exciting initiative. Cochrane Crowd has always been about engaging the public in evidence production, and The People’s Review is the next step in empowering individuals to contribute to systematic reviews directly."

Maureen Smith, a long-time advocate for public involvement in health research, Chair of the Cochrane Consumer Network Executive, and member of ‘Team People’s Review’ highlights the importance of this project:

"The People’s Review involves people in producing evidence, and by doing so it helps to build knowledge about evidence that people need to make informed health choices."

Get Involved and Stay Updated

Everyone, regardless of background or experience, is welcome to join The People’s Review. Whether you have a smartphone, tablet, or computer, you can participate from anywhere in the world. This project is designed to be inclusive and accessible to all.

Be part of this unique opportunity to engage with health research! The project will go through 8 different stages. To stay informed about opportunities to get involved, sign up for the newsletter and be the first to know about each new step in The People’s Review.

• Sign up now and express your interest in participating in The People’s Review
• Follow The People's Review on social media 
  • X
  • Facebook
  • Instagram

The People’s Review is funded by the Health Research Board (Ireland) (ESI-2021-001) and the HSC Research and Development Division of the Public Health Agency (Northern Ireland) through Evidence Synthesis Ireland and Cochrane Ireland. Éle Quinn’s PhD studentship was funded by the College of Medicine, Nursing and Health Sciences, University of Galway, Ireland through Evidence Synthesis Ireland.

An updated Cochrane review has found that the dental health benefits of adding fluoride to drinking water may be smaller now than before fluoride toothpaste was widely available. 

The team of researchers from the Universities of Manchester, Dundee and Aberdeen reviewed the evidence from 157 studies which compared communities that had fluoride added to their water supplies with communities that had no additional fluoride in their water. They found that the benefit of fluoridation has declined since the 1970s, when fluoride toothpaste became more widely available. 

The contemporary studies were conducted in high-income countries. The impact of community water fluoridation in low- and middle-income countries is less clear, due to the absence of recent research.  

Fluoride, used in many commercially available toothpastes and varnishes, is known to reduce tooth decay. Governments in many countries have added fluoride to the drinking water supply to improve population oral health, although there are polarized views on whether this is the right action to take.  

“When interpreting the evidence, it is important to think about the wider context and how society and health have changed over time,” says co-author Anne-Marie Glenny, Professor of Health Sciences Research at the University of Manchester. “Most of the studies on water fluoridation are over 50 years old, before the availability of fluoride toothpaste. Contemporary studies give us a more relevant picture of what the benefits are now.”  

Results from studies conducted after 1975 suggest that the initiation of water fluoridation schemes may lead to slightly less tooth decay in children’s baby teeth. Analysis of these studies, covering a total of 2,908 children in the UK and Australia, estimates that fluoridation may lead to an average of 0.24 fewer decayed baby teeth per child. However, the estimate of effect comes with uncertainty, meaning it’s possible that the more recent schemes have no benefit. By comparison, an analysis of studies with 5,708 children conducted in 1975 or earlier estimated that fluoridation reduced the number of decayed baby teeth, on average by 2.1 per child.  

The same contemporary studies (conducted after 1975) also looked at the number of children with no decay in their baby teeth. The analysis found that fluoridation may increase the number of children with no tooth decay by 3 percentage points, again with the possibility of no benefit. 

The review was only able to draw conclusions about the impact on children’s teeth, with similar findings across both baby and permanent teeth. There were no studies with adults that met the review’s criteria.  

“The evidence suggests that water fluoridation may slightly reduce tooth decay in children,” says co-author Dr Lucy O’Malley, Senior Lecturer in Health Services Research at the University of Manchester. “Given that the benefit has reduced over time, before introducing a new fluoridation scheme, careful thought needs to be given to costs, acceptability, feasibility and ongoing monitoring.” 

Advocates have suggested that one of the key benefits of water fluoridation is that it reduces oral health inequalities. This updated review sought to examine this question and did not find enough evidence to support this claim, although this doesn’t necessarily mean there is no effect. 

The review’s findings accord with recent observational studies including the LOTUS study, which compared anonymised dental health records with water fluoridation status for 6.4 million adults and adolescents in England between 2010 and 2020. People in fluoridated areas needed slightly fewer invasive dental treatments with no significant impact on inequalities. 

“Contemporary evidence using different research methodologies suggest that the benefits of fluoridating water have declined in recent decades,” says Tanya Walsh, Professor of Healthcare Evaluation at the University of Manchester, co-author on both the Cochrane review and the LOTUS study. “Oral health inequalities are an urgent public health issue that demands action. Water fluoridation is only one option and not necessarily the most appropriate for all populations.” 

“Whilst water fluoridation can lead to small improvements in oral health, it does not address the underlying issues such as high sugar consumption and inadequate oral health behaviours,” says co-author Janet Clarkson, Professor of Clinical Effectiveness, University of Dundee. “It is likely that any oral health preventive programme needs to take a multi-faceted, multi-agency approach.” 

• Read the Cochrane review and plain language summary 
• Read the new item in Malay

Iheozor-Ejiofor Z, Walsh T, Lewis SR, Riley P, Boyers D, Clarkson JE, Worthington HV, Glenny A-M, O'Malley L. Water fluoridation for the prevention of dental caries. Cochrane Database of Systematic Reviews TBD, Issue TBD. Art. No.: CD010856. DOI: 10.1002/14651858.CD010856.pub3.

At the United Nations Summit of the Future, two major funding bodies announced £54.2 million of new funding for evidence synthesis: £45 million from Wellcome and £9.2 million from UK Research and Innovation (UKRI).

The announcements represent significant investment in evidence synthesis to help tackle global inequity and address the UN’s Sustainable Development Goals. Cochrane was represented at the summit by our Editor in Chief, Dr Karla Soares-Weiser.

“It is invigorating to see major global funders recognizing the importance of evidence synthesis in addressing the challenges facing the world today and in the future,” says Karla. “This significant investment has the potential to catalyze a step change in evidence synthesis, making it more timely, relevant and equitable. Cochrane has a proud history of advancing evidence synthesis, and we stand ready to support this vital global effort. I am especially excited at the potential to reduce global inequities in both producing and accessing high-quality evidence.”

Both funding calls are aimed at building infrastructure to support rapid evidence synthesis projects so that policymakers have access to the latest evidence on a given topic. The Wellcome announcement focuses on ‘living evidence synthesis’, where systematic reviews are continually updated so they always reflect the latest evidence. Wellcome’s announcement notes that ‘the Cochrane Collaboration, which produces gold-standard evidence syntheses in medicine, increasingly backs living evidence models’.

Cochrane is a pioneer of living systematic reviews, having published the world’s first living systematic reviews in 2017. Lessons from the pilot project were published in 2019, in a project co-led by Professor Tari Turner at Cochrane Australia, who serves on Cochrane’s Editorial Board and is Academic Director of the Australian Living Evidence Collaboration.

“It’s fantastic to see this global commitment to living evidence and recognition of Cochrane's leadership in this area,” says Tari. “The new funding is fantastic news for both evidence synthesis professionals and decision-makers who need up-to-date evidence. Living reviews come with many opportunities and challenges which we identified in our pilot programmes, and it’s great to see them getting the attention they deserve.”

Title: Managing Editor
Specifications: 12 months Fixed Term – Contract
Salary: £42,000 per annum
Location: UK, Germany or Denmark – Remote/Flexible
Closing date: 30 September 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

Reporting to the Senior Managing Editor and working with members of the Editorial Production and Methods Directorate, the role holder will need to have good awareness of Cochrane guidance for different types of standard and complex systematic reviews (intervention, qualitative, diagnostic test accuracy, prognosis, rapid and overview), plan how they will need to be handled in their team, and work to ensure that deadlines are met. The role holder will also be required to ensure that pilots aimed at innovating the editorial process can be supported as needed.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally
• A flexible work environment
• A comprehensive onboarding experiences
• An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 30 September 2024.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Read our Recruitment Privacy Statement

Cochrane is excited to announce that its flagship event, the Cochrane Colloquium, will be hosted in India in October 2026. Building on the momentum of previous successful gatherings, including the Cochrane London Colloquium and the Global Evidence Summit in Prague, this eagerly awaited event will unite the global healthcare evidence synthesis community to foster collaboration, share insights, and drive lasting impact.

The Cochrane Colloquium is an annual international conference that brings together a diverse range of participants, including researchers, healthcare professionals, policymakers, patients, and carers. It provides a unique platform for those passionate about evidence synthesis and evidence-based healthcare to share knowledge, engage in practical workshops, and explore innovative approaches. The event is also a vibrant space for networking, making it a crucial part of the global effort to improve health outcomes through reliable, high-quality evidence.

The 2026 Colloquium will focus on themes that resonate across healthcare and policy sectors: Bridging Gaps, Global Evidence, Local Impact, and Equitable Action. These themes will drive discussions on the importance of evidence in addressing health disparities and achieving equitable healthcare solutions around the world.

Catherine Spencer, CEO of Cochrane, shared her enthusiasm: “The 2026 Cochrane Colloquium will be pivotal for anyone involved in evidence-based healthcare. These themes are crucial for advancing evidence production, implementation, and policy, and we are excited to develop a programme that addresses these vital areas.”

The Cochrane India Network were at the recent Global Evidence Summit. At their stand they engaged with attendees and provided information about the 2026 Cochrane Colloquium, receiving an enthusiastic response. During the closing plenary, they showcased a video and extended a heartfelt invitation to join them in India for the upcoming Colloquium.

Dr Neeta Mohanty from Cochrane India expressed excitement about hosting the Colloquium."It is an honour to invite you all to India for the 2026 Colloquium. Attending previous Colloquia has been a highlight for our team and we are looking forward to welcoming you and being your warm hosts."

We are excited to put together an engaging programme and to bring the community together. Stay tuned for more updates and sign up for the 2026 Colloquium newsletter to keep in touch and be among the first to receive news and announcements.

• Visit the Cochrane India Network website
• Sign up for the 2026 Colloquium newsletter

Specifications: Permanent – Part time (30 hours a week)
Salary: £38,000 per annum full time equivalent
Location: UK (Remote with occasional travel to the London office)
Closing date:  9 Sep 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, Chief Executive Office and Finance and Corporate Services.

This role will sit within the Legal Team in Cochrane’s Finance & Corporate Services Directorate, which also includes the Finance and HR teams.

The Junior Legal Counsel will be required to support the Legal Counsel in providing legal advice to colleagues across the organisation, to enable Cochrane to manage risk and meet its legal and regulatory obligations. In addition to experience in contract law, the successful candidate will have excellent communication and organisational skills, a self-motivated and proactive approach to their work, and an enthusiasm for developing their knowledge and skills.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values:

Collaboration: Underpins everything we do, locally and globally.
Relevant: The right evidence at the right time in the right format.
Integrity: Independent and transparent.
Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally.
• A flexible work environment
• A comprehensive onboarding experiences.
• An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply
• The deadline to receive your application is 9 Sep 2024
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Read our Recruitment Privacy Statement